Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Study Designs in Epidemiology

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.

Bias in Epidemiological Studies

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lessons From an NIH Career: Both/And Thinking to Navigate an Uncertain Future.

Circulation. Cardiovascular quality and outcomes·2025

Same author

Safeguarding integrity and collaborations.

Science (New York, N.Y.)·2023

Same author

National Institutes of Health research project grant inflation 1998 to 2021.

eLife·2023

Same author

From Hype to High-Quality Research.

JAMA network open·2022

Same author

Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.

NAM perspectives·2021

Same author

Inequalities in the distribution of National Institutes of Health research project grant funding.

eLife·2021

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Commentary: Will academia embrace comparative effectiveness research?

Michael S Lauer¹

¹Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, USA. lauerm@nhlbi.nih.gov

Academic Medicine : Journal of the Association of American Medical Colleges

|May 27, 2011

Summary

This summary is machine-generated.

Academic medicine must embrace comparative effectiveness research (CER) to ensure patient safety and improve medical education. By prioritizing high-quality evidence, academic health centers can advance scientific discovery and set a standard for clinical practice.

More Related Videos

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

Area of Science:

Medical Education
Health Services Research
Clinical Trials

Background:

Many widely adopted medical therapies, based on observational data, have proven ineffective or harmful in randomized comparative effectiveness trials (CER).
This reliance on lower-quality evidence negatively impacts medical trainees' education, potentially hindering their ability to critically evaluate evidence and practice evidence-based medicine.
Academic Medicine faces a critical need to integrate CER principles to improve patient outcomes and the quality of medical training.

Discussion:

Academic health centers require cultural shifts to prioritize CER, addressing conflicts of interest and leveraging academic talent and electronic resources.
Effective collaboration with policymakers, integration of economic evaluations, and testing educational methods are crucial for successful CER implementation.
Developing multidisciplinary models and integrating CER into predictive health strategies are essential for advancing academic medicine.

Key Insights:

Academia must champion CER by demanding the highest levels of scientific evidence for all clinical practices.
Every clinical interaction presents an opportunity for scientific advancement and evidence generation.
Academic institutions should lead by example, influencing policymakers and nonacademic settings towards evidence-based practices.

Outlook:

Embracing CER will foster a culture of continuous learning and scientific inquiry within academic medicine.
Integrating CER into all aspects of medical practice and education will enhance patient care and outcomes.
Engaging all physicians in the clinical research enterprise through CER is vital for the future of medicine.